| 1 |
张安邦,高杰,李令根,等.相关炎症因子与动脉粥样硬化的关系[J].中国中西医结合外科,2014,20(5):563-566.
|
| 2 |
Dansky HM,Bloomfield D,Gibbons P,et al. Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia[J]. Am Heart J,2011;162(4):708-716.
|
| 3 |
赵莉,姚树桐,王义围,等. 高密度脂蛋白蛋白成分修饰对其抗动脉粥样硬化功能的影响[J].中国动脉硬化杂志,2014;22(10):1067-1 071.
|
| 4 |
王桂云,逯建华,李鹏,等.ApoB、 ApoB/ApoA Ⅰ值与冠状动脉病变的关系研究进展[J]. 现代中西医结合杂志,2014,23(31):3533-3 5 3 4.
|
| 5 |
唐慧芸,宋道平.脂蛋白(a)对冠心病影响的研究进展[J].全科医疗和社区护理,2013(8):33-35.
|
| 6 |
任宪辉,张英芬,苏咏梅,等.脂蛋白(a)检测对诊断冠状动脉粥样硬化性心脏病的意义[J].医学综述,2010,16(13):2070-2071.
|
| 7 |
蔡国栋,顾扬,刘圣山,等. 血浆脂蛋白相关性磷脂酶A2、 脂蛋白(a)在动脉粥样硬化性脑梗死中的变化及意义[J].实用临床医药杂志,2014,18(16):18-21.
|
| 8 |
胡晓美,王菲. 血清同型半胱氨酸、 血脂水平与冠心病关系研究[J].现代卫生医药,2014,30(23):3548-3549,3551.
|
| 9 |
Miller ER,Juraschek S,Pastor-Barrluso R,et al. Meta analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocystejne levels[J]. Am J Cardiol,2010,106(4):517-527.
|
| 10 |
陆兆华,卢谦,许北柱,等. 高同型半胱氨酸与冠心病的相关性分析[J].牡丹江医学院学报,2013,34(4):24-26.
|
| 11 |
Jabs WJ,Logering BA,Gerke P,et al. Kidney as a second site of human C-reactive protein formation in vivo[J]. Eur J Immunol,2003,33(1):152-161.
|
| 12 |
Szmitko PE,Wang CH,Weisel RD,et al.New markers of inflammation and endothelial cell activation[J].Circulation,2003,108(16):1917.
|
| 13 |
李敬伟,金喆. 血管内超声检测冠脉斑块性质与hs-CRP的相关性[J].中国老年学杂志,2010,30(13):1890-1891.
|
| 14 |
蔡湘丽,韩同亮,李梅,等. 急性冠脉综合征患者循环免疫复合物及超敏C反应蛋白与斑块易损性关系研究[J]. 中国全科医学,2010,13(21):2326-2328.
|
| 15 |
殷乐,李燕,季晓平,等. 兔动脉粥样硬化易损斑块早期预警指标的回归性研究[J].中华心血管病杂志,2011,39(4):343-347.
|
| 16 |
谢良麒,王宪. C反应蛋白与动脉粥样硬化[J]. 生理科学进展,2004,35(2):113-118.
|
| 17 |
Rattazzi M,Puato M,Faggin E,et al. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders[J]? J Hypertens,2003,21(10):1787-1803.
|
| 18 |
王艺霏,王勇,韩超,等. 冠心病患者血清IL-1ra和IL-6水平与冠脉病变程度及预后的相关性研究[J].海南医学,2014,25(20):3017-3 0 2 0.
|
| 19 |
刘春燕.血清脂蛋白相关磷脂酶A2及C反应蛋白与颈动脉粥样硬化斑块易损性的关系[J].中华实用诊断与治疗杂志,2014,28(4):350-3 5 2.
|
| 20 |
Corrado E,Rizzo M,Coppola G,et al. An Update on the Role of Markers of Inflammation in Atherosclerosis[J]. J Atheroscler Thromb,2010,17(1):1-11.
|
| 21 |
Takei A,Huang Y,Lopes-Virella MF,et al. Expression of adhesion molecules by human endothelial cells exposed to oxidized low density lipoprotein. Influences of degree of oxidation and location of oxidized LDL[J].Atherosclerosis,2001,154(1):79-86.
|
| 22 |
Ridker PM,Rifai N,Pfeffer M,et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction[J].Circulation,2000,101(18):2149-2153.
|
| 23 |
Rader DJ. Inflammatory markers of coronary risk[J]. N Engl J Med,2000,343(16):1179-1182.
|
| 24 |
梁彩霞,吴雪松,岳磊. 血清C反应蛋白、 血浆纤维蛋白原、颈动脉粥样硬化与进展性脑梗死的临床研究[J].安徽医药,2014,18(5):914-916.
|
| 25 |
程致,谭明灯,张德权,等. 急性冠状动脉综合征患者血清高敏C反应蛋白和新蝶呤的检测及意义[J].中国基层医药,2006,13(2):2 3 5-2 3 7.
|
| 26 |
徐荣丰,高大胜,王红雷,等. 血清新蝶呤和单核细胞趋化蛋白-1在冠心病患者血清中的表达及意义[J]. 中国心血管病研究杂志,2007,5(6):420-423.
|
| 27 |
吕永楠,蒋学俊,戴雯,等. 新蝶呤在冠状动脉粥样硬化中的临床应用[J].中华检验医学,2014;37(7):513-516.
|
| 28 |
宗同岩,蔡九英,宋晓坤,等. YKL40 一个新的心血管生物标志物[J].中国老年学,2011,5(31):1918-1920.
|
| 29 |
黄春秀,刘远智. 冠心病患者血清可溶性CXCL16、 hs-CRP和YKL-40的变化及意义[J].实用医学杂志,2010;26(23):4410-4412.
|
| 30 |
Schober A,Bernhagen J,Thiele M,et al. Stabilization of atherosclerotic plaques by blockage of macrophage migration inhibitory factor after vascular injury in apolipoprotein in E-deficient mice[J].Circulation,2004,109(3):380-385.
|
| 31 |
Methia N,Andre P,Denis CV,et al. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice[J]. Blood,2001,98(5):1424-1428.
|
| 32 |
王建军,杨超,张琦,等. D-二聚体与急性冠脉综合征冠脉病变的相关性[J].山西医科大学学报,2014,45(12):1169-1171.
|